Peginterferon beta-1a
Peginterferon beta-1a (Peginterferon β-1a) is the first pegylated interferon beta-1a molecule. Peginterferon beta-1a induces cancer cells apoptosis and shows anti-tumor activities in nude mice models. Peginterferon beta-1a can be used for the research of cancer and multiple sclerosis (RMS).
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1211327-92-2
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
In Vitro
Peginterferon beta-1a (0.001-1000 ng/mL; 5 d) affects cell viability of SK-MEL-2, SK-MEL-5, MeWo and WM-266-4 tumor cells[1]. Peginterferon beta-1a (10, 100, and 1,000 ng/mL) induces cell apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SK-MEL-1, SK-MEL-2, SK-MEL-5, MeWo and WM-266-4 tumor cell lines
-
Concentration:0.001-1000 ng/mL
-
Incubation Time:5 d
-
Result:Inhibited the cell viability of SK-MEL-2, SK-MEL-5, MeWo and WM-266-4 tumor cells and showed an IC50 value of 2-3 ng/mL to WM-266-4 cells.
-
Cell Line:WM-266-4 cell line
-
Concentration:10, 100 and 1000 ng/mL
-
Incubation Time:24 h
-
Result:Induced the cleavage of PARP, caspase-8, and -9, induction of TRAIL and phosphorylation of STAT1.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice with human SK-MEL-1 and A-375 melanoma xenografts[1]
-
Dosage:0.1-1.6 mg/kg
-
Administration:Subcutaneous injection; once/twice a week; for 3/4 weeks
-
Result:Significantly inhibited SK-MEL-1 tumor growth at 0.4 mg/kg (QW; 3 w) and inhibited A-375 melanoma tumors at 1.6 mg/kg (BIW; 4 w).
-
Animal Model:Nude mice with human WM-266-4 melanoma xenografts[1]
-
Dosage:0.4-1.6 mg/kg
-
Administration:Subcutaneous injection; 0.4-1.6 mg/kg; once/twice/three times a week for 4 w
-
Result:The QW dose of 1.6 mg/kg and all doses given BIW and TIW induced tumor regression, with a 1.6 mg/kg QW dose induced significant tumor inhibition relative to 0.8 mg/kg QW.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1211327-92-2
-
SMILES
[Peginterferon beta-1a]
-
Synonyms
Peginterferon β-1a
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)